Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02911649
Other study ID # 16-5437
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date March 2019

Study information

Verified date April 2021
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cancer-related fatigue (CRF) can be experienced by individuals with Prostate Cancer (PC), which can have profound effects on their well-being. Although physical activity has been shown to improve CRF, the recommended levels are generally not met. Step count and distance traveled information can help individuals to increase their physical activity. Wearable technology (WEAR) provides the user with feedback of their physical activity which can motivate behaviour change. Similarly, education workshops (EDU) on the effects of sedentary behaviour and physical activity may also reduce sedentary behaviour. The objectives of this study are to evaluate the effects of WEAR and EDU on sedentary behaviour and CRF, and to explore the feasibility of WEAR in this population. Participants in this study will be randomly assigned into WEAR, EDU, WEAR+EDU, or control over a three-month intervention. Assessments at baseline, post-intervention and a 3-month follow up will evaluate CRF, quality of life and level of sedentary behaviour, and use of WEAR devices. The results from this study will provide evidence-based knowledge on the impact of WEAR and EDU on sedentary behaviour and CRF, and an understanding on the use of technology within the PC population. These results can shape the development of programming for CRF and the use of scale-able technology-based interventions/approaches in this population.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date March 2019
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - PC survivors aged 18 years or older - Currently sedentary, defined as <90 minutes per week of activity - Fluent in English - Access to a computer with internet connectivity Exclusion Criteria: • Men who are or have received chemotherapy

Study Design


Intervention

Other:
Wearable Technology - Garmin Vivosmart
Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
Online Educational Group
A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
Wearable Technology - FitBit Alta
Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
Wearable Technology - Polar Loop 2
Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.

Locations

Country Name City State
Canada University Health Network Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
University Health Network, Toronto University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment rate At baseline we will evaluate the recruitment rate of participants for the feasibility of this trial and reasons for declining to participate Baseline
Primary Retention rate At the end of the intervention and follow-up assessment, we will measure retention rate through number of participants who have withdrawn from the study. 3 month assessment (Post-Intervention)
Primary Adherence Adherence will be measured for participants attendance throughout the intervention. 3 month assessment (Post-Intervention)
Primary WEAR device preference This will be measured through the number of participants that choose each of the three devices. 3 month assessment (Post-Intervention)
Primary Acceptability Acceptability will be measured through the end of study questionnaire at the follow-up assessment 6 months assessment (follow-up)
Primary Outcome measures captured This will be measured through review and analysis of data obatined for completeness 6 month assessment (follow-up)
Secondary Cancer-Related Fatigue Assessed with Functional Assessment of Cancer Therapy - Fatigue (FACT-F) Baseline, 3 month assessment(post-intervention), 6 month assessment (3 month Follow up)
Secondary Sedentary Behaviour Assessed through accelerometry and Sit-Q 7 Day questionnaire Baseline, 3 month assessment(post-intervention), 6 month assessment (3 month Follow up)
Secondary Quality of Life Assessed with Functional Assessment of Cancer Therapy - General (FACT-G) Baseline, 3 month assessment(post-intervention), 6 month assessment (3 month Follow up)
Secondary Depression Assessed with Patient Health Questionnaire - 9 (PHQ-9) Baseline, 3 month assessment(post-intervention), 6 month assessment (3 month Follow up)
Secondary Understand attitudes towards using wearable technology Assessed through semi-structured interviews Baseline, 3 month assessment(post-intervention), 6 month assessment (3 month Follow up)
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2